Effects of trimetazidine therapy on left ventricular function after percutaneous coronary intervention

Chinese Journal of Cardiology

Volumn 41, Issue 3, 2013, Pages 205-209

  Xu, Xiao Han ^a   Zhang, Wei Jun ^a   Zhou, Yu Jie ^a   Zhou, Zhi Ming ^a   Ma, Han Ying ^a   Hu, Bin ^a   Rang, Yun Peng ^a   Luo, Fang Fang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Trimetazidine; Troponin; Ventricular function, left

Indexed keywords

TRIMETAZIDINE;

ARTICLE; CONTROLLED STUDY; DEATH; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; TRIMETAZIDINE; VENTRICULAR FUNCTION, LEFT;

EID: 84876783347     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2013.03.007     Document Type: Article

References (14)

1. Fuchs S, Gruberg L, Singh S, et al. Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndrome. Am J Cardiol, 2001, 88: 129-133.
2. Cantor W J, Newby L K, Christenson R H, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol, 2002, 39: 1738-1744.
3. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart, 2007, 93: 703-707.
4. Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs, 2007, 7:143-150.
5. 2007, 35:295-304.
6. Grube E, Gerckens U, Yeung A C, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation, 2001, 104: 2436-2441.
7. Kantor P F, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000, 86:580-588.
8. 2008, 36: 36-39.
9. Bucci M, Borra R, Någren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther, 2012, 30:333-341.
10. Zhou X, Li C, Xu W, et al. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One, 2012, 7:e40424.
11. Liu X, Gai Y, Liu F, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res, 2010, 88:150-158.
12. Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol, 2011, 34:395-400.
13. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart, 2011, 97:278-286.
14. 2009, 89:1399-1401.